MedTrace Logo

Effect of Neuromuscular Electrical Stimulation on the Post-Operative Abdominoplasty Patient.

NCT05229692 · Status: WITHDRAWN · Phase: NA · Type: INTERVENTIONAL

Last updated 2023-08-09

No results posted yet for this study

Summary

The purpose of this study is to determine the impact of rehabilitative training of the abdominal wall with direct current neuromuscular electrical stimulation (the NEUBIE device) on recovery time from abdominoplasty (tummy tuck).

Conditions

  • Rectus Diastasis

Interventions

DEVICE

NEUBIE

Participants will be asked to undergo electrical stimulation with the NEUBIE at their "treatment threshold". Treatment threshold will be described as "uncomfortable," but not "painful" (a 7 out of 10 on a perceived intensity scale). Session length: ≤ 30 minutes Treatment frequency: 2x per week for 5 weeks Week 1 post-op (treatments 1-2) Activity: Passive Neubie on Abdominals \& Obliques Weeks 2-3 (treatments 3-6) * Passive Neubie * Isometric movements with Neubie on abdominals and obliques * Active mobilizations with Neubie on abdominals and obliques Weeks 4-5 (treatments 7-10) * Active mobilizations with Neubie on abdominals and obliques * Core Strength Exercise circuit with Neubie on abdominals and obliques

Sponsors & Collaborators

  • University of Texas at Austin

    collaborator OTHER

  • NeuFit - Neurological Fitness and Education

    lead INDUSTRY

Principal Investigators

  • Rocco Piazza, MD · University of Texas - Austin

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-06-25
Primary Completion
2023-08-01
Completion
2023-12-01
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05229692 on ClinicalTrials.gov